Floatz logo

PYY(3-36)

Feeding and Eating Disorders

Gila Therapeutics, Inc.protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Feeding and Eating Disorders cohort.

Asset / SponsorPhaseRating
Semaglutide
University Hospital Sestre Milosrdnice
Phase 4BB
2-Bromo-?-ergocryptine
University of North Carolina, Chapel Hill
Phase 3BB
Rimonabant
Sanofi
Phase 3CC
Octreotide Pamoate
St. James's Hospital, Ireland
D
GLUCAGON-LIKE PEPTIDE 1, HUMAN
Haukeland University Hospital
D

View all 10 →

Same molecule, other indications

PYY(3-36) is also rated in:

obesity disorderDormant
CCC
Indicative ·
48 / 100
View asset →
morbid obesityDormant
D
Indicative ·
30 / 100
View asset →
type 2 diabetes mellitusDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →